Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins

Cátia Cantante, Sara Lourenço, Maurício Morais, João Leandro, Lurdes Gano, Nuno Silva, Paula Leandro, Mónica Serrano, Adriano O. Henriques, Ana Andre, Catarina Cunha-Santos, Carlos Fontes, João D.G. Correia, Frederico Aires-da-Silva, Joao Goncalves

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Recombinant antibody fragments belong to the promising class of biopharmaceuticals with high potential for future therapeutic applications. However, due to their small size they are rapidly cleared from circulation. Binding to serum proteins can be an effective approach to improve pharmacokinetic properties of short half-life molecules. Herein, we have investigated the Zag albumin-binding domain (ABD) derived from Streptococcus zooepidemicus as a novel strategy to improve the pharmacokinetic properties of therapeutic molecules. To validate our approach, the Zag ABD was fused with an anti-TNFα single-domain antibody (sdAb). Our results demonstrated that the sdAb-Zag fusion protein was highly expressed and specifically recognizes human, rat and mouse serum albumins with affinities in the nanomolar range. Moreover, data also demonstrated that the sdAb activity against the therapeutic target (TNFα) was not affected when fused with Zag ABD. Importantly, the Zag ABD increased the sdAb half-life ∼39-fold (47 min for sdAb versus 31 h for sdAb-Zag). These findings demonstrate that the Zag ABD fusion is a promising approach to increase the half-life of small recombinant antibodies molecules without affecting their therapeutic efficacy. Moreover, the present study strongly suggests that the Zag ABD fusion strategy can be potentially used as a universal method to improve the pharmokinetics properties of many others therapeutics proteins and peptides in order to improve their dosing schedule and clinical effects.

Original languageEnglish
Pages (from-to)23-33
Number of pages11
JournalJournal of Biotechnology
Volume253
DOIs
Publication statusPublished - 10 Jul 2017

Fingerprint

Single-Domain Antibodies
Streptococcus equi
Antibodies
Half-Life
Albumins
Proteins
Pharmacokinetics
Fusion reactions
Molecules
Therapeutics
Immunoglobulin Fragments
Serum Albumin
Rats
Blood Proteins
Appointments and Schedules
Peptides

Keywords

  • Albumin binding domain
  • Antibody engineering
  • Half-life extension
  • Recombinant antibodies
  • Streptococcus
  • ZAG protein

Cite this

Cantante, Cátia ; Lourenço, Sara ; Morais, Maurício ; Leandro, João ; Gano, Lurdes ; Silva, Nuno ; Leandro, Paula ; Serrano, Mónica ; Henriques, Adriano O. ; Andre, Ana ; Cunha-Santos, Catarina ; Fontes, Carlos ; Correia, João D.G. ; Aires-da-Silva, Frederico ; Goncalves, Joao. / Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins. In: Journal of Biotechnology. 2017 ; Vol. 253. pp. 23-33.
@article{987427a33db54d1994407dda5ae651ed,
title = "Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins",
abstract = "Recombinant antibody fragments belong to the promising class of biopharmaceuticals with high potential for future therapeutic applications. However, due to their small size they are rapidly cleared from circulation. Binding to serum proteins can be an effective approach to improve pharmacokinetic properties of short half-life molecules. Herein, we have investigated the Zag albumin-binding domain (ABD) derived from Streptococcus zooepidemicus as a novel strategy to improve the pharmacokinetic properties of therapeutic molecules. To validate our approach, the Zag ABD was fused with an anti-TNFα single-domain antibody (sdAb). Our results demonstrated that the sdAb-Zag fusion protein was highly expressed and specifically recognizes human, rat and mouse serum albumins with affinities in the nanomolar range. Moreover, data also demonstrated that the sdAb activity against the therapeutic target (TNFα) was not affected when fused with Zag ABD. Importantly, the Zag ABD increased the sdAb half-life ∼39-fold (47 min for sdAb versus 31 h for sdAb-Zag). These findings demonstrate that the Zag ABD fusion is a promising approach to increase the half-life of small recombinant antibodies molecules without affecting their therapeutic efficacy. Moreover, the present study strongly suggests that the Zag ABD fusion strategy can be potentially used as a universal method to improve the pharmokinetics properties of many others therapeutics proteins and peptides in order to improve their dosing schedule and clinical effects.",
keywords = "Albumin binding domain, Antibody engineering, Half-life extension, Recombinant antibodies, Streptococcus, ZAG protein",
author = "C{\'a}tia Cantante and Sara Louren{\cc}o and Maur{\'i}cio Morais and Jo{\~a}o Leandro and Lurdes Gano and Nuno Silva and Paula Leandro and M{\'o}nica Serrano and Henriques, {Adriano O.} and Ana Andre and Catarina Cunha-Santos and Carlos Fontes and Correia, {Jo{\~a}o D.G.} and Frederico Aires-da-Silva and Joao Goncalves",
year = "2017",
month = "7",
day = "10",
doi = "10.1016/j.jbiotec.2017.05.017",
language = "English",
volume = "253",
pages = "23--33",
journal = "Journal of Biotechnology",
issn = "0168-1656",
publisher = "Elsevier Science B.V., Inc",

}

Cantante, C, Lourenço, S, Morais, M, Leandro, J, Gano, L, Silva, N, Leandro, P, Serrano, M, Henriques, AO, Andre, A, Cunha-Santos, C, Fontes, C, Correia, JDG, Aires-da-Silva, F & Goncalves, J 2017, 'Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins', Journal of Biotechnology, vol. 253, pp. 23-33. https://doi.org/10.1016/j.jbiotec.2017.05.017

Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins. / Cantante, Cátia; Lourenço, Sara; Morais, Maurício; Leandro, João; Gano, Lurdes; Silva, Nuno; Leandro, Paula; Serrano, Mónica; Henriques, Adriano O.; Andre, Ana; Cunha-Santos, Catarina; Fontes, Carlos; Correia, João D.G.; Aires-da-Silva, Frederico; Goncalves, Joao.

In: Journal of Biotechnology, Vol. 253, 10.07.2017, p. 23-33.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins

AU - Cantante, Cátia

AU - Lourenço, Sara

AU - Morais, Maurício

AU - Leandro, João

AU - Gano, Lurdes

AU - Silva, Nuno

AU - Leandro, Paula

AU - Serrano, Mónica

AU - Henriques, Adriano O.

AU - Andre, Ana

AU - Cunha-Santos, Catarina

AU - Fontes, Carlos

AU - Correia, João D.G.

AU - Aires-da-Silva, Frederico

AU - Goncalves, Joao

PY - 2017/7/10

Y1 - 2017/7/10

N2 - Recombinant antibody fragments belong to the promising class of biopharmaceuticals with high potential for future therapeutic applications. However, due to their small size they are rapidly cleared from circulation. Binding to serum proteins can be an effective approach to improve pharmacokinetic properties of short half-life molecules. Herein, we have investigated the Zag albumin-binding domain (ABD) derived from Streptococcus zooepidemicus as a novel strategy to improve the pharmacokinetic properties of therapeutic molecules. To validate our approach, the Zag ABD was fused with an anti-TNFα single-domain antibody (sdAb). Our results demonstrated that the sdAb-Zag fusion protein was highly expressed and specifically recognizes human, rat and mouse serum albumins with affinities in the nanomolar range. Moreover, data also demonstrated that the sdAb activity against the therapeutic target (TNFα) was not affected when fused with Zag ABD. Importantly, the Zag ABD increased the sdAb half-life ∼39-fold (47 min for sdAb versus 31 h for sdAb-Zag). These findings demonstrate that the Zag ABD fusion is a promising approach to increase the half-life of small recombinant antibodies molecules without affecting their therapeutic efficacy. Moreover, the present study strongly suggests that the Zag ABD fusion strategy can be potentially used as a universal method to improve the pharmokinetics properties of many others therapeutics proteins and peptides in order to improve their dosing schedule and clinical effects.

AB - Recombinant antibody fragments belong to the promising class of biopharmaceuticals with high potential for future therapeutic applications. However, due to their small size they are rapidly cleared from circulation. Binding to serum proteins can be an effective approach to improve pharmacokinetic properties of short half-life molecules. Herein, we have investigated the Zag albumin-binding domain (ABD) derived from Streptococcus zooepidemicus as a novel strategy to improve the pharmacokinetic properties of therapeutic molecules. To validate our approach, the Zag ABD was fused with an anti-TNFα single-domain antibody (sdAb). Our results demonstrated that the sdAb-Zag fusion protein was highly expressed and specifically recognizes human, rat and mouse serum albumins with affinities in the nanomolar range. Moreover, data also demonstrated that the sdAb activity against the therapeutic target (TNFα) was not affected when fused with Zag ABD. Importantly, the Zag ABD increased the sdAb half-life ∼39-fold (47 min for sdAb versus 31 h for sdAb-Zag). These findings demonstrate that the Zag ABD fusion is a promising approach to increase the half-life of small recombinant antibodies molecules without affecting their therapeutic efficacy. Moreover, the present study strongly suggests that the Zag ABD fusion strategy can be potentially used as a universal method to improve the pharmokinetics properties of many others therapeutics proteins and peptides in order to improve their dosing schedule and clinical effects.

KW - Albumin binding domain

KW - Antibody engineering

KW - Half-life extension

KW - Recombinant antibodies

KW - Streptococcus

KW - ZAG protein

UR - http://www.scopus.com/inward/record.url?scp=85019767367&partnerID=8YFLogxK

U2 - 10.1016/j.jbiotec.2017.05.017

DO - 10.1016/j.jbiotec.2017.05.017

M3 - Article

VL - 253

SP - 23

EP - 33

JO - Journal of Biotechnology

JF - Journal of Biotechnology

SN - 0168-1656

ER -